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 Chapter 16 
 Establishing the Links Between Ab Aggregation and 
Cytotoxicity In Vitro Using Biophysical Approaches 
 Asad  Jan and  Hilal  A.  Lashuel  
 Abstract 
 Aggregation and fi bril formation of the amyloid- b (A b ) peptides play a pivotal role in the pathogenesis of 
Alzheimer’s disease (AD). The missing links on the pathway to A b oligomerization, fi bril formation, and 
neurotoxicity in AD remain the identity of the toxic A b species and mechanism(s) of their toxicity. Such 
information is crucial for the development of mechanism-based therapeutics to treat AD and tools to 
diagnose and/or monitor the disease progression. Herein, we describe a simple approach that combines 
standard biophysical methods with cell biology assays to correlate the aggregation state of A b peptides 
with their cytotoxicity in vitro. The individual assays are well-established, commonly used, rely on easily 
accessible materials and can be performed within 24 h. 
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 Alzheimer’s disease (AD) is the most common cause of debilitating 
dementia in elderly worldwide. Despite signifi cant advances in the 
understanding of the mechanisms of A b production and aggregation 
in vitro, translating this knowledge in a clear mechanistic under-
standing of the pathogenesis of AD and effective clinical therapies 
remain challenging. Circumstantial evidence, principally derived 
from neuropathology, molecular genetics, animal models of AD, 
cell culture studies, and biophysics indicate that the aggregation 
and fi bril formation of amyloid- b (A b ) peptides play central role in 
AD pathogenesis  ( 1,  2 ) . A b peptides are produced as a conse-
quence of sequential proteolytic processing of the amyloid pre-
cursor protein (APP) by  b - and  g -secretase activities. APP cleavage 
by  g -secretase results in production of A b peptides of various 
chain lengths, principally composed of 40 and 42 amino acid 
 1.  Introduction
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residues (A b 40 and A b 42), which densely populate the core of 
the neuritic plaques in AD neuropathology  ( 3 ) . During the 
in vitro fi bril formation of A b peptides, various nonfi brillar aggre-
gates of diverse morphologies and heterogeneous size distributions, 
collectively known as the soluble oligomers, have been observed. 
Some of the well-characterized A b oligomer species include proto-
fi brils  ( 4 ) , A b -derived diffusible ligands (ADDLs)  ( 5 ) , annular 
oligomers  ( 6 ) , and the low molecular weight oligomers  ( 7 ) . 
 Several independent lines of evidence indicate that the soluble 
oligomers and/or the process of oligomerization  ( 8– 10 ) , rather 
than plaque-associated fi brils, are the primary cause of neurode-
generation in AD: (1) Soluble A b , rather than total (soluble and 
insoluble) A b , levels correlate better with AD progression  ( 11,  12 ) ; 
(2) Signifi cant functional defi cits in the memory performance tasks 
are observed in the APP transgenic animals long before the emer-
gence of amyloid plaques  ( 13,  14 ) ; (3) Soluble A b oligomer prepa-
rations, upon intracerebral infusion, induce transient memory 
defi cits in experimental animals  ( 15 ) ; (4) Rare mutations in the 
APP gene [e.g., arctic mutation (E22G)], which enhance A b oli-
gomerization without altering the total A b levels, are associated 
with the development of familial AD  ( 16 ) ; (5) A b oligomer and 
protofi bril preparations alter neuronal metabolism  ( 17 ) , induce 
changes in neuronal electrophysiology  ( 18 ) and lead to neurotox-
icity towards cultured neurons  ( 10,  17,  19 ) . Therefore, inhibiting 
A b oligomerization, by attenuating its production and/or pro-
moting the clearance of toxic A b oligomers from brain, has 
emerged as potential therapeutic strategies for treating AD  ( 20 ) . 
 Cultured primary neurons and/or cell lines provide easy and 
economic means of investigating the role of A b aggregation state 
and the mechanism of A b toxicity, and also as valuable tools for the 
screening of the inhibitors of A b toxicity in vitro. This chapter 
describes simple, inexpensive, and reproducible methods which 
would allow the investigators to assess the toxicity of A b prepara-
tions (soluble or insoluble) and correlating A b aggregation/
fi brillization with its cytotoxicity. The general outline is provided 
in Fig.  1 . Briefl y, cultured cells are treated with purifi ed A b prepa-
rations (monomers, protofi brils, and fi brils) or crude preparations 
containing mixtures of heterogeneous A b species. For detailed 
protocols on the preparation of these species, the reader is referred 
to our previous work  ( 10,  21 ) . At desired intervals, cell viability is 
determined by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) reduction assay. In the case of primary 
neurons, subtle changes in neuronal viability can also be quantifi ed 
using immunostaining for neuronal nuclei (NeuN)  ( 8 ) or via 
quantifi cation of the loss of neuronal processes  ( 19,  21 ) . In addition, 
media aliquots of A b -treated cultured cells can be used to investi-
gate the cytotoxicity and the aggregation state of A b simultaneously. 
Quantitative cytotoxicity information can be obtained by performing 
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the lactate dehydrogenase (LDH) release assay using the cell culture 
medium. Finally, a direct link between the extent of cytotoxicity 
and A b aggregation state can be established by combining these 
assays with methods that allow monitoring of A b aggregation in 
the cultured media, e.g., dye [Thiofl avin T (ThT)] binding and 
negative-staining transmission electron microscopy (TEM). 
 This approach will allow the researchers to closely monitor 
changes in the quaternary structure of A b under cell culture 
 Fig. 1.  Overview of the methods used to correlate A b aggregation with cytotoxicity in vitro. Cultured cells (primary 
neurons and/or cell lines) are treated with the desired concentration(s) of the purifi ed or crude A b preparations  ( 21 ) . 
At selected intervals, cell viability can be assessed by the MTT reduction assay. In the case of neuronal cultures, immu-
nostaining for neuronal nuclei (NeuN)  ( 8 ) or neuronal processes  ( 19 ) can also be used. The culture medium can be assayed 
for cytotoxicity using the LDH release method. In addition, A b aggregation and fi brillization can be monitored by ThT 
dye binding and TEM analysis of the culture medium and allow for the correlation of the A b aggregation with the rela-
tive cytotoxicity (the MTT graph and the LDH release graphs are reprinted with copyright permission  ( 10,  19 ) ). Labels in 
the MTT graph: cultured primary neurons, PC12 and SHSY5Y cells were treated with different A b preparations (10  m M total 
A b ) or the buffer vehicle and cell viability was assessed by the MTT reduction assay ( Veh buffer vehicle,  CR crude A b 42 
preparations,  PF A b 42 protofi brils,  M A b 42 monomers,  A b 40 A b 40 monomers)  ( 10 ) . Labels in the LDH graph: cultured 
primary neurons were treated with A b 40-arctic (E22G) monomers (20  m M total A b ) and cell viability was assessed over 
time by the LDH release in the culture medium and quantitative immunocytochemistry for the microtubule-associated 
protein (MAP) and neurofi lament-M (NF-M)  ( 19 ). 
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conditions, formation of oligomers and fi brils during the duration 
of the experiment, and most importantly, directly correlate A b 
aggregation state(s) with relative cytotoxicity. The knowledge 
gathered from such studies is indispensable for the identifi cation of 
the critical stages (aggregation states) on the A b amyloid formation 
pathway which underlie A b cytotoxicity and help design the inter-
vention strategies. Herein, we describe the use of MTT reduction 
and the LDH release assays for quantifying A b toxicity toward 
cultured PC12 cells. Detailed methods for culturing primary 
neurons, including immunostaining and measuring cell viability by 
relevant assays, have been described elsewhere  ( 8,  21 ) . 
 MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide] belongs to the group of tetrazolium salts which, upon endo-
cytosis by the cells, is reduced to the insoluble formazan crystals 
principally by the activity of the mitochondrial respiratory chain 
enzymes  ( 22 ) . In addition, certain enzymes in cytoplasm, endo-
somes/lysosomes, and plasma membrane have also been impli-
cated in the metabolism of MTT into the formazan  ( 23 ) . 
Metabolically active and viable cells can reduce the MTT in short 
durations of time, e.g., 30 min, into purple formazan products the 
formation of which can be monitored spectrophotmetrically 
(Fig.  2 )  ( 23 ) . It is one of the most commonly used assays to monitor 
cytotoxicity of various drugs, synthetic polymers, and amyloid 
proteins  ( 17,  24,  25 ) . Numerous research groups have shown that 
A b preparations containing monomers, oligomers, or fi brils consis-
tently impair the ability of cultured neurons or other cells to 
metabolize MTT  ( 9,  17,  26 ) . The simple nature of the assay and 
 1.1.  MTT Reduction 
Assay
 Fig. 2.  Principle of the MTT assay. MTT is internalized by the cells and reduced by the action of various cellular dehydrogenases, 
principally in mitochondria, into the purple formazan product. The crystals of formazan are solubilized and the absorbance 
(570 nm) of the resulting solution provides a measure of the cellular viability. 
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the lack of requirements for expensive instrumentation make it a 
convenient choice for assessing the relative toxicity of A b preparations 
and also for the evaluation of the A b aggregation inhibitors in 
rescuing the survival of A b -treated cells. 
 Although it is very easy to perform, some shortcomings of the 
assay are worth mentioning: (1) the assay does not differentiate 
between cell death and metabolic stress  ( 27 ) ; (2) the readout is 
semiquantitative, i.e., a decrease in MTT reduction does not 
correlate with number of dead cells in a linear fashion  ( 27 ) ; 
(3) different cell types metabolize MTT, and related tetrazolium 
dyes, to differential extent, i.e., the assay readout is infl uenced by 
the metabolic phenotype of the cells  ( 28 ) ; and (4) it has also been 
suggested that amyloidogenic proteins interfere with crystallization 
of MTT formazan in a manner such that the extent of cytotoxicity 
is overestimated  ( 9 ) . Therefore, it is highly recommended that 
MTT reduction assay be used in conjunction with some other 
biochemical and/or immunocytochemical means of assessing the 
cell viability, e.g., LDH release assay (see below) and/or, in the 
case of neurons, staining for the loss of neuronal processes. 
 LDH is an oxidoreductase enzyme present in the cytoplasm of a 
wide variety of cells and catalyzes the interconversion of pyruvate 
and lactate, coupled to the concomitant interconversion of NADH 
and NAD +  ( 29,  30 ) . Cell membrane disruption, during various 
physiological or pathological processes, leads to the release of the 
enzyme in extracellular milieu (e.g., cell culture medium). Hence, if 
appropriate substrates are added to the culture medium, the levels of 
LDH release, and therefore the extent of cell membrane damage, 
can be quantifi ed (Fig.  3 ). LDH release is also a commonly used 
assay for investigating the biosafety of drugs and for assessing the 
cytotoxicity of the amyloidogenic proteins including A b  ( 31,  32 ) . 
 1.2.  LDH Release 
Assay
 Fig. 3.  Principle of the LDH release assay. Upon  membrane disruption/cell damage,  the cytosolic LDH is released into 
the extracellular milieu/tissue culture medium. In the presence of appropriate substrates and cofactors,  the enzyme 
activity results in  the formation of colorimetric/fl uorescent products. The latter can be quantifi ed and indicate the extent 
of cytotoxicity. 
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Interestingly, it has been observed that in neuronal cultures exposed 
to A b oligomers, loss of neuronal processes precedes the rise in LDH 
release. The latter observations suggest that A b oligomer toxicity is 
mediated by multiple mechanisms and the neurodegeneration 
commences long before the frank death of neurons  ( 9,  10,  18,  19 ) . 
 In contrast to the MTT reduction assay, the amount of LDH 
release provides a more reliable measure of the number of dead/
damaged cells  ( 33 ) . However, it is also known that different cell 
types have differential LDH content and/or the kinetics of the 
LDH release is not identical  ( 34 ) ; therefore, correlation of the 
assay readout to the extent of cell death between different cell types 
cannot be accurately determined. Nevertheless, the combined 
application of the two assays (MTT and LDH) provides valuable 
information regarding both the early and the late events associated 
with A b cytotoxicity. 
 Electron microscopy (EM)-based approaches have played important 
role in our current understanding of the mechanism of amyloid 
formation of nearly all amyloidogenic proteins, and also in elucidating 
the structural basis of amyloid toxicity. As early as 1960s, these 
approaches facilitated the detailed structural characterization of 
amyloid aggregates associated with neuropathological lesions in 
AD brains  ( 35 ) . In addition, EM methods have also played impor-
tant role in the discovery and structural characterization of various 
A b oligomers, including protofi brils, which precede the emergence 
of fi brils during the aggregation of A b peptides  ( 4,  17 ) . The latter 
fi ndings signifi cantly changed the paradigm of understanding the 
interrelation of the process of amyloid formation and associated 
neurodegeneration, and ushered the notion of toxic oligomer/
protofi bril hypothesis  ( 36 ) . Although, the toxicity of plaque-associated 
fi brillar aggregates is not ruled out, this hypothesis points toward 
soluble A b oligomers as neurotoxins in AD and stipulates that the 
A b oligomers trigger a complex series of the cellular and molecular 
events culminating in the development of AD  ( 36 ) . A detailed 
description of various EM-based methods and their utility in 
studying amyloid aggregation can be found elsewhere  ( 21,  37 ) . 
 Herein, we describe the methods and use of the negative-staining 
EM on the cell culture media aliquots to study A b aggregation 
under cell culture conditions, and directly establish the correlation 
of the aggregate structure with their respective cytotoxicity in 
neuronal and nonneuronal cell culture systems. In brief, cell culture 
medium aliquots are deposited on carbon-coated formvar fi lm 
attached to an EM grid, followed by the staining with a dilute solu-
tion of a heavy salt (uranyl acetate, uranyl formate etc.). The latter 
help enhance the contrast in the images by their ability to scatter 
electrons in the incident electron beam. Although, a convenient 
and simple method, the quality of the information obtained by 
negative-staining EM is limited by certain factors such as: (1) limited 
resolution capability ( » 2.5 nm) of the technique, (2) drying of the 
 1.3.  Negative-Staining 
TEM
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surface causes fl attening of the aggregate structures, (3) the aggregates 
may differ in their adsorption to the grid surface, (4) image artifacts 
can be induced by uneven staining of the sample (this could be 
addressed by preparing multiple grids of the sample), and (5) most 
importantly, it is not a quantitative method. Therefore, it is sug-
gested that information about the characterization of amyloid 
aggregates should be complimented by other standard biophysical 
assays, e.g., Thiofl avin-T (ThT) dye binding and solubility analysis 
by the size exclusion chromatography  ( 6,  8 ) . 
 Thiofl avin-T (4-(3,6-dimethyl-1,3-benzothiazol-3-ium-2-yl)- N , N -
dimethylaniline chloride), and its homologue Thiofl avin-S, is a 
benzothiazole salt and belongs to the so-called amyloid-specifi c 
dyes. The thiofl avin dyes undergo red shift in their emission spectrum 
upon binding to amyloid plaques in amyloid laden tissue sections 
 ( 38,  39 ) . In vitro, thiofl avin dyes bind to the ordered amyloid 
aggregates such as fi brils and protofi brils of diverse proteins, e.g., 
A b  ( 8,  17 ) ,  a -synuclein  ( 40 ) , but not to the low molecular weight 
oligomers (2–12 mers) or monomers  ( 8,  17 ) . The specifi city of the 
dyes for binding to the amyloid structures has been proposed to be 
based on the presence of the cross-strand ladders, characteristic 
arrangements of side chains, present in  b -sheet-rich structures, and 
formation of channels along the  b -sheet surfaces which allow for 
the binding of linear thiofl avin dyes (Fig.  4 )  ( 41 ) . Although very 
simple and inexpensive method, ThT binding per se does not 
always provide a quantitative measure of the amount of amyloid 
aggregates, e.g., a small amount of fi brils in A b preparations can 
result in high-ThT values. Also, extensive fi brillization, and inter-
twining of the fi brils, may reduce the accessibility of ThT dyes 
towards the binding sites thus erroneously decreasing the ThT 
readout. Nevertheless, changes in ThT binding in kinetic assays is 
a reliable indicator of the metastability in amyloid aggregates and, 
if used in combination with cytotoxicity assays, is a reliable correlate 
of extent of cytotoxicity with amyloid aggregation. 
 
  1.  Human wild-type (wt) synthetic A b 42 and A b 40 from a suitable 
commercial source (e.g., W.M. Keck Facility, Yale University, 
New Haven, CT, USA). 
  2.  Trizma ® hydrochloride solution (Tris–HCl) 1 M (Sigma, cat. 
no. T2663). 
  3.  Uranyl acetate (UA) (Electron Microscopy Sciences, cat. no. 
22400). 
  4.  Formvar-coated TEM grids (Electron Microscopy Sciences, 
cat. no. FCF200-Cu-50). 
 1.4.  Thiofl avin-T Dye 
Binding
 2.  Materials
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  5.  Grid storage box (Electron Microscopy Sciences, cat. no. 71140). 
  6.  High Precision Ultrafi ne tweezers (Electron Microscopy 
Sciences, cat. no. 78318-3X). 
  7.  Thiofl avin-T (ThT) (Sigma, cat. no. T3516). 
  8.  Glycine (Sigma, cat. no. 50046). 
  9.  Sterile microtubes (e.g., Eppendorf cat. no. Z606340). 
  10.  Dulbecco’s Modifi ed Eagle’s Medium (DMEM) (Invitrogen, 
cat. no. 41966-029). 
  11.  DMEM (Invitrogen, cat. no. 21063-029). 
  12.  Recombinant insulin (Invitrogen, cat. no. 12585014). 
  13.  Phosphate-buffered saline (PBS; GIBCO, cat. no. 10010-015). 
  14.  Fetal bovine serum (FBS; GIBCO, cat. no. 10101145). 
  15.  Penicillin–streptomycin (Pen–Strep, 100×; GIBCO, cat. no. 
15140-122). 
  16.  LDH cytotoxicity assay kit (Sigma, cat. no. TOX7). 
  17.  MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) (Sigma, cat. no. M5655). Prepare 5 mg/ml MTT 
 Fig. 4.  Mechanism of ThT binding to the amyloid aggregates. ( a ) Structure of ThT. ( b ) Cross- b structure of amyloid fi brils, 
formed from layers of laminated  b -sheets. ThT is proposed to bind along surface side-chain grooves running parallel to the 
long axis of the  b -sheet. ( c ) Characteristic increase in ThT fl uorescence upon binding to amyloid fi brils. ( d ) TIRF microscopy 
image of branched glucagon fi brils stained with ThT (Images ( a – c ) are reprinted with copyright permission  ( 41 ) . The TIRF 
image ( d ) is reprinted with copyright permission  ( 42 ) ). 
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stock solution in sterile PBS and fi lter through 0.22- m m 
syringe-driven fi lter units (TPP, cat. no. 99722). The stock 
solution should be aliquoted in sterile microtubes (1 ml/tube) 
and frozen at −20°C. 
  18.  96-Well, transparent bottom, cell culture plates (BD Falcon, 
cat. no. 353072). 
  19.  384-Well plates, black (Nunc, cat. no. 262260). 
  20.  Dimethyl sulfoxide (DMSO) (Sigma, cat. no. D4540). 
  21.  1 N Hydrochloric acid solution (Sigma, cat. no. H9892). 
  22.  Microplate reader (e.g., Safi re 2, TECAN). 
  23.  Poly-L-Lysine (PLL) 0.01% solution (Sigma, cat. no. P4832). 
  24.  Rat pheochromocytoma (PC12) cells: PC12 cells are commer-
cially available (e.g., ATCC, cat. no. CRL-1721) and should 
be grown in DMEM (Invitrogen, cat. no. 41966-029) supple-
mented with 1% Pen–Strep and 10% FBS (5% horse-serum, in 
addition to 10% FBS, during early passages) in 75-cm 2 culture 
fl asks (37°C; ambient humidity; 5% CO 2 ). It is recommended 
that the cells should be split before they reach complete con-
fl uence (twice/week), to record the number of passages and to 
keep some frozen stocks of the cells. 
 
 Detailed methods for the preparation and characterization of the 
crude A b preparations, containing heterogeneous A b aggregation 
states and monomers, or defi ned A b species including monomers, 
protofi brils, and fi brils have been described previously  ( 8,  21 ) . 
  1.  Plate PC12 cells in 96-well, transparent bottom, culture plates 
previously coated with 0.01% PLL (30,000 cells/well/200  m l) 
in the culture medium consisting of phenol red-free DMEM 
medium (Invitrogen, cat. no. 21063-029) supplemented with 
1% Pen–Strep and 2  m M recombinant insulin. The cells should 
be grown in culture plates for at least 24 h (37°C; ambient 
humidity; 5% CO 2 ), and should be treated with A b preparation 
within 24–48 h after plating (see Note 1). 
  2.  Dilute the A b preparations (Subheading  3.1 ) in the culture 
medium at twice the fi nal concentration(s) desired to be tested 
(see Note 2). For example, if the desired test A b concentration 
is 10  m M, dilute the A b preparations to 20  m M in appropriate 
volume of the culture medium. 
  3.  Remove 100 ml of the culture medium from each condition 
and control well and discard into a waste container. 
 3.  Methods
 3.1.  Preparation of 
Crude A b Preparations, 
Purifi ed Monomers, 
Protofi brils, and Fibrils
 3.2.  Toxicity of A b 
Preparations in PC12 
Cell Cultures
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 Fig. 5.  Fibrillization and relative toxicities of the soluble A b 42 preparations. Cultured PC12 cells were treated with purifi ed 
A b 42 preparations ( M monomers,  PF protofi brils, 1:1 molar mixtures of the monomers and protofi brils, i.e., 5  m M of each). 
The fi nal A b concentration was  » 10  m M. ( a ) MTT reduction over time. A b 42 protofi brils and mixtures of A b 42 protofi brils 
with A b 42 monomers signifi cantly inhibit MTT reduction. In addition, the MTT reduction is signifi cantly impaired with 
6–9 h of A b 42 treatment. The values are expressed as percentage of the buffer control (the error bars represent s.d. in 
at least six replicate conditions). ( b ) LDH release. Mixture of A b 42 protofi brils and A b 42 monomers cause early and robust 
increase in the LDH release as compared to the monomers, protofi brils, and fi brils alone. The values are expressed as 
percentage of the buffer control (the error bars represent s.d. in at least six replicate conditions). ( c ) ThT binding. Mixture 
of A b 42 protofi brils and A b 42 monomers fi brillize faster and to a greater extent than the monomers or protofi brils alone. 
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  4.  Add 100  m l of culture medium containing A b preparations, 
prepared in Subheading  3.2 , step 2 to each condition well. To 
establish statistical signifi cance, across different conditions and 
across different experiments, at least 4–6 wells should be 
treated with each A b preparation. 
  5.  Include medium only treated and buffer sample (prepared in 
identical fashion as the A b preparations in step 2) treated cells 
as controls. If performing a time course study, the controls 
should be included for each time point. 
  6.  At desired intervals (e.g., every hour), carefully remove 150  m l 
of the culture medium, without touching the well bottom, into 
sterile microtubes and label accordingly. The removed medium 
will be used for assays outlined below (Subheadings  3.4 – 3.6 ). 
  7.  Carefully remove the rest of the medium and discard. 
  1.  Wash the cells by adding 200  m l of sterile PBS (room temperature) 
into each well and remove carefully without disturbing the cells 
in the bottom of the wells. Perform the PBS wash 2–3 times 
and discard into a waste container. 
  2.  Add 100  m l of the fresh culture medium containing 5% (vol./vol.) 
MTT dye solution to each well and place the cells back in the 
incubator for 2–4 h (see Note 3). 
  3.  Carefully remove the culture medium and discard into a waste 
container. Then, add 100  m l of the 100% DMSO to each well 
(see Note 3). 
  4.  Solubilize the cells by careful pipetting and transfer the contents 
into empty wells of another 96-well plate. Transfer the latter 
plate to a 4°C chamber for storage not exceeding 24 h. 
  5.  Repeat steps 1–4 above at each desired time point and collect 
the cell lysates. In order to avoid differential evaporation across 
the culture plates, add 200 µl of sterile water to each empty 
well before placing the plate back in the incubator. 
  6.  Warm the plate containing the cell lysate collected from each 
time point above, to 20–25°C [room temperature (RT)] by 
simply leaving the plate on a desk for 15 min. 
 3.3.  MTT Reduction 
Assay
Fig. 5. (continued) The  error bars represent s.d. in at least six replicate conditions (a.u. = arbitrary units). ( d – k ) Representative 
images obtained by negative-staining TEM of the culture medium. ( d ,  e ) A b 42 monomers at time 0 and 24 h respectively; 
( f ,  g ) A b 42 protofi brils at time 0 and 24 h respectively; ( h ) Equimolar mixtures of A b 42 monomers and protofibrils and 
( k ) A b 40 monomers at 24 h ( scale bar = 200 nm). These data show that an ongoing process of A b oligomerization 
and fi brillization, rather than discrete A b species (monomers, protofi brils, or fi brils), critically impairs cell viability  ( 9,  10 ) . 
In other words, dynamics of the protofi bril–monomers interactions and the resultant growth of the protofi brils into fi brils 
is more important determinant of A b toxicity than relatively stable protofi bril species  ( 8,  10 ) . This hypothesis is also 
supported by the observations that enhancing the kinetic stability of A b 42 protofi brils by adding A b 40 monomers signifi -
cantly reduces their toxicity toward cultured neurons  ( 8 ) . Similarly, small molecules that stabilize A b protofi brils in vitro 
have also been shown to improve behavioral performance in APP transgenic mice  ( 43 ). 
 Fig. 6.  Fibrillization and relative toxicities of A b 40 monomers and A b 42 fi brils. Cultured PC12 
cells were treated with A b 40 monomers and A b 42 fi brils. The fi nal A b concentration was 
 » 10  m M. ( a ) MTT reduction over time. Both A b 40 monomers and A b 42 fi brils cause slight, but 
insignifi cant, reduction in MTT metabolism by the cultured cells. The values are expressed as 
percentage of the buffer control (the  error bars represent s.d. in at least six replicate conditions). 
( b ) LDH release. A b 42 fi brils cause relatively greater release of the cellular LDH as compared 
to A b 40 monomers (the  error bars represent s.d. in at least six replicate conditions). ( c ) ThT 
binding. The ThT binding by A b 40 monomers remains relatively unchanged over time 
suggesting lack of fi bril formation. The  error bars represent s.d. in at least six replicate condi-
tions (a.u. = arbitrary units). ( d ,  e ) Representative images obtained by negative-staining 
TEM of the culture medium. ( d ) A b 42 fi brils and ( e ) A b 40 after 24 h ( scale bar = 200 nm). 
 
23916 Establishing the Links Between Aβ Aggregation and Cytotoxicity In Vitro…
  7.  Record the absorbance at 570 nm using a microplate reader. 
Use a wavelength in the range of 630–750 nm (e.g., 690 nm) 
as a reference wavelength to account for the plate background, 
cell debris, nonspecifi c absorbance etc. 
  8.  Plot the data in a suitable software (Figs.  5a and  6a ). 
  1.  Prepare LDH assay mixture according to the manufacturer’s 
recommendations (Sigma, cat. no. TOX7). 
  2.  Vortex the tubes containing culture medium removed in 
Subheading  3.2 , step 6 from each test and control condition. 
  3.  Separately add 50  m l of each test sample in empty wells of a 
transparent 96-well plate. 
  4.  Add 100  m l of the LDH assay mixture to each well. 
  5.  Include the culture medium as a control sample. 
  6.  Incubate the plate at 37°C for 20–30 min. Protect from light. 
  7.  To stop the reaction, add 15  m l of 1 N HCl to each well. 
  8.  Record the absorbance at 490 nm using a microplate reader. 
Use a wavelength in the range of 630–750 nm (e.g., 690 nm) 
as a reference wavelength to account for the plate background, 
cell debris, nonspecifi c absorbance etc. 
  9.  Plot the data in a suitable software (Figs.  5b and  6b ). 
  1.  Vortex the tubes containing culture medium removed in 
Subheading  3.2 , step 6 from each test and control condition. 
  2.  Mix 80  m l of the culture medium with 10  m l of 100  m M ThT 
(see Note 4) and 10  m l of 500 mM glycine–NaOH pH 8.5 in 
corresponding wells of a Nunc 384 black well plate (see Note 5). 
Each sample should be assayed in at least duplicates. 
  3.  Acquire ThT fl uorescence values in a suitable fl uorescence 
microplate reader using an excitation wavelength 450 nm and 
emission wavelength 485 nm (see Note 6). 
  4.  Plot the data in a suitable software (see Figs.  5c and  6c ). 
  1.  Vortex the tubes containing culture medium removed in 
Subheading  3.2 , step 6 from each test and control condition. 
  2.  On a formvar-coated TEM grid, apply 2–10  m l of one of the 
samples and let the droplet settle for ~60 s (see Note 7). 
  3.  Then, using a blotting paper gently wick the edge of the sample 
grid and remove excess solution. 
  4.  Apply a 10  m l droplet of negative-staining solution (e.g., 2% 
wt/vol. UA) and let it settle for ~60 s on the grid surface 
(see Note 8). 
  5.  Remove the excess solution as in step 3 above. 
 3.4.  LDH Release 
Assay
 3.5.  Thiofl avin-T Assay
 3.6.  Transmission 
Electron Microscopy
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  6.  Using a fi ne vacuum probe, gently vacuum dry the grid from the 
edges. Sample grids not examined immediately can be stored in 
a storage box in a dry place (e.g., a desiccating chamber). 
  7.  Acquire images on a CM10 TEM (or equivalent TEM), 
equipped with a CCD camera, operated at an acceleration 
voltage of 80–100 kV (Figs.  5d–h and  6d , e). 
 
  1.  Other cell lines of neural origin (e.g., human neuroblastoma 
SHSY5Y cells) and/or primary neurons can be used as well. 
For culturing primary neurons, see the methods described 
elsewhere  ( 21 ) . 
  2.  Excessive dilution of A b samples can be avoided by preparing 
the A b stock samples in supplemented 10× DMEM (e.g., 
Sigma, cat. no. D2429)  ( 10 ) or modifi ed 100× neurobasal 
medium  ( 21 ) . 
  3.  Alternatively, commercially available kits can also be used with 
appropriate modifi cations to the procedure (e.g., Promega, 
cat. no. G4000). 
  4.  A 100  m M stock solution of ThT can be prepared as follows: 
Dissolve 0.32 mg of ThT in 10 ml of ultrapure H 2 O and vortex 
until a particulate-free solution is achieved. Filter the solution 
using a 0.22- m m PES syringe fi lter. Aliquot the volume needed 
for the day (Subheading  3.5 , step 2 ) and store the rest at 4°C. 
The solution can be stored at 4°C for 2–3 months. The presence 
of precipitates warrants immediate disposal. Protect from light 
by wrapping the tube in aluminum foil. To prepare 500 mM 
glycine–NaOH pH 8.5 solution, dissolve 376 mg of glycine in 
10 ml of ultrapure H 2 O until clear. Bring the pH to 8.5 by 
drop by drop addition of 1 N NaOH and continuous mixing. 
Filter the solution with a 0.22- m m PES syringe fi lter and store 
at 4°C. Remove the volume needed for the day (Subheading  3.5 , 
step 2), and store the rest at 4°C for up to 2–3 months. Presence 
of precipitates warrants immediate disposal. 
  5.  The described step is optimized for fi nal concentration of 
A b  £ 10  m M, ThT:A b ratio  ³ 1 and final glycine–NaOH 
concentration being 50 mM. The step can be modifi ed to 
accommodate different concentrations of A b . For example: 
For a sample of 50  m M A b , either dilute the sample with normal 
culture medium to 10  m M and proceed as above or use 70 mM 
glycine–NaOH stock solution (20  m l A b + 70  m l glycine–
NaOH + 10  m l ThT (100  m M). 
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  6.  In addition to the excitation and emission wavelengths, adjust 
the settings of the fl uorometer as follows: (1) number of reads 
(5–10); (2) plate (Nunc 384-well black); (3) Z-height (middle 
of the well); (4) integration time (100 ms); and (5) reading 
interval (10 × 10 ms). 
  7.  To reduce the TEM grid surface contamination and hydro-
phobicity, it is recommended to apply the glow discharge the 
grids prior to the sample application. 
  8.  A 2% wt/vol. UA stock solution can be prepared as follows: 
Dissolve 200 mg of UA in 10 ml of ultrapure H 2 O and vortex 
until a particulate-free solution is achieved. Filter the solution 
using a syringe-driven 0.22- m m PES fi lter and store at 4°C. 
The solution should be prepared as needed and can be stored 
at 4°C for 1 month. Dispose of the solution as per institutional 
regulations. Wear gloves while handling. 
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